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Abstract
Background: Obesity and overweight are major public health problems. Various factors, such as daily
nutritional habits, physical inactivity, and genetic, are related to the prevalence of obesity. Recently, it was
revealed that the gut microflora may also play an important role in weight management. Thus, this study
aimed to determine the anti-obesity effects of Lactobacillus casei strain Shirota (LcS) compared with those of
orlistat in an animal model fed a high-fat diet (HFD).
Design: Thirty-two male Sprague-Dawley rats were assigned to four groups fed various diets as follows:
a standard diet group, HFD group, HFD supplemented with LcS (108109 colony-forming units (HFD-LcS)
group, and HFD group treated with Orlistat (10 mg/kg body weight)). After 15 weeks, the weights of organs,
body weight, body fat mass and serological biomarkers were measured. In addition, histological analysis of
the liver and adipose tissue was performed.
Results: Body weight, body mass index, fat mass, leptin and glucose levels were lower, and high-density
lipoprotein and adiponectin levels were higher in the HFD-LcS and HFD-orlistat groups than in the HFD
group. In addition a significant difference in body fat mass was observed between HFD-LcS group with HFD-
orlistat group (19.1995.76 g vs. 30.1997.98 g). Although the interleukin-6 level was significantly decreased
in the HFD-LcS and HFD-orlistat groups compared with the HFD group, no significant change was observed
in other inflammatory biomarkers.
Conclusion: The results of the present study show that LcS supplementation improves body weight man-
agement and the levels of some related biomarkers. In addition, LcS supplementation showed a better result in
fat mass and alanine aminotransferase reduction than Orlistat. Further studies are needed to elucidate the
anti-obesity effects of LcS, with a longer period of supplementation.
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O
besity and overweight are major public health
problems and recently became a pandemic (1). In
2014, more than 1.9 billion adults were over-
weight, of whom more than 600 million were obese,
worldwide (2). Bibbins-Domingo et al. (3) estimated that
the prevalence of obesity will increase by 7% among men
and 10% among women by 2020. Obesity and overweight
increase the incidence of cardiovascular disease, stroke,
type 2 diabetes (4), and several types of cancer (5, 6).
Obesity is related to poor eating habits and sedentary
lifestyles. People often consume dietary supplements that
can affect their health, despite providing essential nutri-
ents like vitamins and minerals for their body. In this
context, products containing probiotic microorganisms
are included. Probiotics are defined as live microorganisms
that can confer beneficial health effects if administered in
adequate amounts. Accumulating evidence reveals a
potential association between specific strains of bacteria
and obesity (1, 7, 8). The structure of gut microbiota is
changed in obese animals (811) and humans (1214).
Recent data suggest that probiotic supplements affect host
nutritional metabolism, which affects energy storage,
adiposity, and nutrient absorption (1, 15). Several mecha-
nisms have been proposed that link events in the colon with
the regulation of energy metabolism. However, the effects
of different species of bacteria on long-term weight loss
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and the detailed underlying mechanisms remain unknown.
Lactobacillus casei strain Shirota (LcS) is a bacterial strain
that is commercially available as a probiotic in many
countries (16) and has beneficial health effects (17, 18). In
addition, drugs such as Orlistat are effective for weight
management (19) by decreasing the leptin level and fat
mass. However, given the high prevalence of obesity,
identifying an effective treatment strategy is an ongoing
struggle. Supplementing the diet with probiotics may be an
alternative strategy for combating obesity and related
disorders (20). Therefore, we aimed to determine and
compare the effects of LcS, which was isolated from a fer-
mented milk drink, with those of Orlistat on body weight
and levels of related biomarkers in high fat diet-induced
obese rats. A comparative analysis was also conducted
within and between groups treated with LcS or Orlistat.
Materials and methods
Animals and experiments
Thirty-two 6-week-old male Sprague-Dawley rats were
purchased from Central Lab Animal Inc. (Malaysia). The
rats were fed a standard diet (AIN-76A, Dyets Inc.,
Bethlehem, PA, USA) for 2 weeks to stabilize all metabolic
conditions and achieve a weight of9200 g. Food and water
were supplied ad libitum. Each cage contained one rat.
After 2 weeks, rats were randomly selected and assigned
to one of four groups (eight rats per group). Rats in group
1 were fed a standard diet (SD) and those in groups
24 were fed a high fat diet (HFD, 40% w/w beef tallow
modified AIN-76A purified rodent diet) for 12 weeks.
The nutritional content of experimental diets is shown in
Table 1. This study was approved by the Animal Care and
Use Committee of the Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia.
After 12 weeks of obesity induction, rats in group 1 were
assigned to the SD group, and those in groups 24 were
assigned to the HFD group, the HFD supplemented
with LcS (HFD-LcS) group and the HFD group treated
with 10 mg/kg body weight Orlistat (HFD-orlistat),
respectively. Rats in the HFD-LcS group were orally
administered LcS [108109 colony-forming units (CFU)]
once per day for 15 weeks. Rats in the HFD-orlistat group
were gavaged with Orlistat daily, and those in the SD and
HFD groups were gavaged with water daily. Body weight
was measured weekly. Body mass index (BMI) was
measured at baseline (week 12) and at the end of the study
(week 27), and was calculated as body weight (g) divided
by the square of the analnasal length (cm2).
Waist circumference (WC; cm) was measured during
anesthesia at week 12 and at the end of the study (week
27) using a standard measuring tape calibrated to 0.1 cm.
Rats were placed in a recumbent position, the measuring
tape was placed beneath the rat, and the measurement
was taken around the transverse plane.
Body fat and organ weights
After sacrificing the rats, body fat including retroperito-
neal, mesenteric, and inguinal fat were measured. The liver,
spleen, kidney, heart, and pancreas were removed and
weighed using standard weighing scales calibrated to 0.1 g.
Bacterial concentration determination
The viable plate count method was used to prepare 108109
CFU of LcS to gavage the rats. Bacteria were extracted
from a fermented milk drink commercially available in a
supermarket and identified by 16S rRNA using a ZR
Fungal/Bacteria DNA MiniPrepTM Kit (catalogue num-
ber: D6005; Zymo Research, Irvin, CA, USA). After
extraction, the bacterial strain was cultured in de Man,
Rogosa and Sharpe (MRS) broth (Sigma-Aldrich) and
incubated at 378C for 24 h. Bacteria were harvested by cen-
trifugation at 5,000 rpm for 5 min. After centrifuge, auto-
claved normal saline was added to the isolated bacteria.
The bacterial suspension was used within 15 min.
Serological analysis
Blood samples were collected at weeks 12 and 27 by heart
puncture using sterilized tube during anesthesia. Serum
samples were analyzed in terms of the blood glucose level,
the lipid profile, including levels of low-density lipoprotein
(LDL), triglyceride (TG), high-density lipoprotein (HDL),
and total cholesterol (T-chol) and liver function tests, includ-
ing levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), using HITACHI COBAS C311
reagents from Roche Diagnostics (Germany). Moreover,
levels of inflammatory factors, such as interleukin 6 (IL-6),
tumor necrosis factor-a (TNF-a), and C-reactive protein
(CRP); pro-inflammatory factors, such as leptin; and anti-
inflammatory markers, such as adiponectin, were mea-
sured using enzyme-linked immunosorbent assay (ELISA)
Table 1. Composition of experimental diet
Ingredients
Standard diet
(g/kg diet)
Energy
(kcal)
High-fat diet
(g/kg diet)
Energy
(kcal)
Casein 200 720 200 720
Beef tallow 0 0 400 3,600
Methionine 3 12 3 12
Starch 150 540 150 540
Sucrose 500 2,000 150 600
Cellulose 50 0 50 0
Corn oil 50 450 0 0
Vitamin mixture 10 39 10 39
Mineral mixture 35 30.8 35 30.8
Choline
bitartrate
2 2 2 2
Total 1,000 3791.8 1,000 5541.8
Modified AIN-76-A diet (1).
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kits according to the manufacturer’s instructions (RayBio
Enzyme Immunoassay Kit, USA).
Food intake measurement
Food consumption was measured daily by subtracting the
final weight in grams (i.e. weight of the empty food jar and
spilt food) from the initial weight (i.e. weight of the full
food jar measured on the previous day). A balance was
used to weigh the food and jar.
Histological analysis
After sacrificing the rats, the liver and adipose tissues
were dissected, washed thoroughly with normal saline,
trimmed, processed, and embedded in paraffin. The liver
and adipose tissues were sectioned at a thickness of 45
mm and stained with hematoxylin and eosin (H&E). The
slides were examined under a light microscope by a
specialist who was blinded to the study.
Statistical analysis
Results were presented as mean9standard error (SE).
Data were evaluated for statistical significance using a one-
way ANOVA. A significantly different group was identi-
fied using the least significant-difference test (LSD), which
was conducted with SPSS software (SPSS, Inc.). PB0.05
was considered statistically significant.
Results
Anthropometric changes, organ weights, and food intake
An upward trend in body weight was observed in all
groups every week. Within the 27-week study period, rats
in the HFD group showed a significant increase in body
weight (Fig. 1a). Table 2 shows the anthropometric
changes (weight, height, BMI, and WC), organ weights,
and fat mass of rats in the four groups. The body weight of
rats in the SD and HFD groups was significantly higher at
week 27 than at week 12. The HFD group exhibited the
largest weight gain (379.58911.68 g), followed by the SD
group (262.398.45 g), the HFD-LcS group (253.2198.10
g), and the HFD-orlistat group (221.9595.87 g) (Fig. 1b).
The BMI of rats in the HFD-LcS and HFD-orlistat groups
was significantly lower at week 27 than at week 12.
Although the final body weight of rats in the HFD-LcS
group was significantly lower than that of rats in the HFD
group (488.4397.08 g vs. 597.83917.09 g), there was no
significant difference in daily food intake between the two
groups (HFD group: 15.7991.26 g/day vs. HFD-LcS
group: 13.6592.31 g/day). Daily food intake was signifi-
cantly higher in the HFD group than in the SD group
(10.2891.16 g/day, pB0.05) (Fig. 1c). Thus, caloric intake
was higher in the HFD group, which explains the increase
in body fat mass.
Moreover, rats in the HFD-LcS group had a signifi-
cantly lower BMI (0.6590.02 g/cm2 vs. 0.7590.06 g/cm2),
WC (18.3890.57 cm vs. 21.0890.8 cm), and fat mass
(19.1995.76 g vs. 35.7898.96 g) than rats in the HFD
group. There was no significant difference in the weight of
the spleen, kidney, heart, or pancreas between the HFD-
LcS group and the other groups. In contrast to body
weight, BMI and WC, which did not significantly differ
between the HFD-LcS and HFD-orlistat groups, body fat
mass significantly differed between these two groups
(19.1995.76 g vs. 30.1997.98 g).
Fig. 1. Effect of LcS on a) body weight; b) weight gain; c) food intake.
SD: standard diet; HFD: high fat diet; HFD-LcS:high fat diet supplemented with LcS; HFD-orlistat: high fat diet treated with
Orlistat.
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Serological analyses
Table 3 shows the blood glucose level, lipid profile (TG,
HDL, LDL, and T-chol), and levels of inflammatory
markers (IL-6, TNF-a, and CRP), pro-inflammatory mar-
kers (leptin), anti-inflammatory markers (adiponectin), and
liver function biomarkers (AST and ALT) in each group.
The serum levels of glucose, leptin, and ALT in the
HFD-LcS group were significantly lower at week 27 than
at week 12, with no significant changes in inflammatory
biomarkers. The same trend was observed in the HFD-
orlistat group. Furthermore, the adiponectin and HDL
levels in the HFD-LcS and HFD-orlistat groups were
significantly higher at week 27 than at week 12.
The comparison of serological biomarkers among the
groups is summarized in Table 3. The levels of glucose, TG,
IL-6, and leptin were significantly lower in the HFD-LcS and
HFD-orlistat groups than in the HFD group at week 27,
whereas the levels of adiponectin and HDLwere significantly
increased. The serological biomarkers did not significantly
differ between the HFD-LcS and HFD-orlistat groups.
Histological analysis
H&E staining of white adipose tissue indicated that the
size of adipocytes in HFD-LcS group was significantly
smaller than those in the HFD group (Fig. 2a). Unlike
the HFD and HFD-orlistat group, no significant macro-
vesicular steatosis was observed in HFD-LcS group.
Furthermore, no adverse effects, such as inflammation,
necrosis, and hemorrhage in hepatocytes, were observed
in the liver tissue of rats supplemented with LcS (Fig. 2b).
Discussion
Effects of LcS on body weight, fat mass, and organs weight
Recent studies highlighted that some bacterial strains,
such as Lactobacillus spp. and Bifidobacterium spp., play a
role in energy metabolism and weight management in
obese rats and humans (2123). Identifying which bacter-
ial strain should be used as a probiotic supplement is
extremely important because it has been suggested that the
health-promoting properties of probiotics are strain-
dependent (24). Several mechanisms underlie how bacterial
strains elicit their functions (21, 25, 26).
In the present study, we analyzed and compared the
anti-obesity effects of the probiotic strain LcS with those
of orlistat in HFD-induced obese rats. At the end of the
27-week study, HFD rats demonstrated the largest gain
Table 2. Effect of LcS on anthropometric, fat mass, and organs weight
SD group HFD group HFD-LcS group HFD-orlistat group
Body weight (g)
0 week 221.56911.43 218.2599.08 230.2297.69 225.25910.8
12th week 396.22912.29 491.63932.32 491.63920.22 497.13920.55
27th week 483.86915.72a 597.83917.09b 488.4397.08a 447.20915.68a
p value within groups 0.001* 0.02* 0.89 0.11
Height (cm) 23.1192.90 27.5490.24 19.6994.31 19.4094.24
12th week 27.2690.46 28.0890.45 27.3690.26 26.2490.46
27th week 0.23 0.27 0.12 0.23
p value within groups
Waist circumference (cm)
12th week 14.590.46 17.8790.56 16.890.71 17.090.56
27th week 18.9390.58b 21.0890.8b 18.3890.57a 18.190.81ab
p value within groups 0.21 0.14 0.20 0.31
BMI (g/cm2)
12th week 0.5990.02 0.6590.05 0.7390.03 0.7590.03
27th week 0.6590.06a 0.7590.06b 0.6590.02a 0.6590.06a
p value within groups 0.059 0.14 0.02* 0.03*
Fat mass (g) 14.8191.62a 35.7898.96b 19.1995.76a 30.1997.98b,c
Liver (g) 15.791.08b 15.191.29b 11.390.94a 12.0290.54b
Kidney (g) 3.2190.421 2.8790.67 2.5390.57 1.5990.61
Spleen (g) 0.7290.107 0.5890.13 0.7690.23 0.4990.19
Heart (g) 1.4590.09 1.6090.09 1.4790.11 1.4490.60
Pancreas (g) 0.50990.203 0.56190.188 0.56090.11 0.53690.172
SD: standard diet, HFD: high-fat diet, HFD-LcS: high-fat diet supplemented with LcS, HFD-orlistat: high-fat diet treated with orlistat. Data are
mean9SE, SE: standard error, *data are significantly different at week 27 compared with those in week 12 (within groups analysis, paired t-test).
a,b,cData with different superscript letters are significantly different at week 27, pB0.05, according to the post hoc ANOVA statistical analysis (LSD),
(between groups analysis).
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Table 3. LcS effect on serological biomarkers (within groups and between groups analysis)
SD Group HFD Group HFD-LcS Group HFD-orlistat Group
T-cholesterol
12th week 1.6390.11 1.3690.09 1.3090.16 1.2390.06
27th week 1.5990.13 1.4190.11 1.3190.1 1.2490.13
p 0.8 0.7 0.95 0.94
LDL-c
12th week 0.2890.03 0.1890.06 0.2790.07 0.1490.03
27th week 0.2590.03 0.1990.03 0.2390.03 0.1790.02
p 0.55 0.81 0.58 0.48
HDL-c
12th week 1.0690.06 0.8790.08 0.8890.08 0.8190.05
27th week 1.1790.18 0.6890.07a 1.0590.12b 1.2890.21bc
p 0.49 0.11 0.02* 0.013*
TG
12th week 0.5990.05 0.6190.1 0.7690.22 0.7590.13
27th week 1.0490.10 1.2690.44a 0.8390.15b 0.7590.24b
p 0.001* 0.13 0.81 0.94
Leptin
12th week 5.8891.39 11.7992.01 24.4692.26 35.6491.02
27th week 2.6790.80a 13.5992.35b 7.1491.42c 5.0292.90cd
p 0.08 0.49 0.001* 0.001*
Adiponectin
12th week 78.022931.48 69.71941.60 63.59915.49 51.71917.18
27th week 319.4992.31bcd 67.8291.62a 266.98910.9b 187.7198.39bc
p 0.01* 0.3 0.02* 0.02*
IL-6
12th week 66.1192.22 74.8893.05 93.9097.06 87.1796.23
27th week 105.9918.62a 100.76913.83a 92.7298.93b 82.63915.62b
p 0.013* 0.05* 0.98 0.88
TNF-a
12th week 359.893.44 354.593.02 365.294.0 362.394.09
27th week 357.893.46 357.197.50 355.595.38 357.0195.10
p 0.7 0.32 0.16 0.42
hs-CRP
12th week 0.2690.01 0.2290.02 0.2690.01 0.2590.01
27th week 0.2590.01 0.2590.02 0.2890.02 0.2890.01
p 0.61 0.33 0.28 0.09
AST
12th week 47.6291.79 54.4892.27 60.7395.21 57.4693.77
27th week 100.00916.91a 102.9093.20a 64.6697.20b 65.33910.68
p 0.003* 0.5 0.66 0.41
ALT
12th week 20.2491.70 24.3593.36 33.3894.82 26.8994.55
27th week 31.6696.42a 35.4893.52a 16.4793.51b 20.1895.75
p 0.07* 0.01* 0.016* 0.3
Glucose
12th week 6.2290.2 6.2990.26 8.6790.68 9.1191.17
27th week 9.3091.34 10.3591.42a 6.2390.18b 6.1590.35b
p 0.02* 0.07* 0.03* 0.01*
SD: standard diet, HFD: high-fat diet, HFD-LcS: high-fat diet supplemented with LcS, HFD-orlistat: high-fat diet treated with orlistat.
Data are mean9SE. Data with different superscript letters are significantly different pB0.05, according to the post hoc ANOVA statistical analysis
(LSD).
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weight; however, rats in the HFD-LcS group had a lower
body weight, fat mass, and liver weight. Body weight
reduction reflects a negative status of energy expenditure,
which can be due to food intake reduction or energy
expenditure stimulation (27). In the present study, there
was no significant difference in food intake between the
supplemented groups and the control group; therefore, the
body weight reduction could be due to higher energy
expenditure and changes in the intestinal barrier. A HFD
increased the endotoxemia through increasing the intes-
tine permeability by reducing the expression of some genes
that are encoded for tight junction proteins in the colon
(28). Probiotics can increase the function of the intestinal
barrier, leading to body weight loss (29). It has been also
suggested that the oral administration of probiotics
increases the activity of the sympathetic nervous system
in white and brown adipose tissue and that the intragastric
administration of probiotics increases lipolysis in white
adipose tissue and thermogenesis in brown adipose tissue.
Thus, probiotic consumption facilitates thermogenic and
lipolytic responses via stimulating the sympathetic nervous
system, which leads to weight reduction (15).
Effects of LcS on serological biomarkers and tissue histology
The effects of LcS administration on serological biomar-
kers were examined. The leptin level was significantly
lower in LcS-supplemented rats than in rats in the HFD
group. This is consistent with the results of previous
studies indicating there is an association between body and
fat weight reduction and a reduced level of leptin in
humans (30) and animals (1, 31). Leptin is exclusively
produced by white adipose tissue (32), which acts as a
global messenger to the central nervous system of systemic
energy storage in order to control food intake and energy
expenditure (33). Adipocyte size is an important factor for
the expression of leptin and its release into blood (34).
Therefore, the reduced concentration of leptin in the
HFD-LcS group versus that in the HFD group may be
due to a higher proportion of small adipocytes, which
decreases food intake and increases energy expenditure.
Another serological biomarker that decreased in obese
individuals is adiponectin, a type of adipokine that is
specifically produced by adipose tissue and regulates
insulin sensitivity and tissue inflammation (35). Weight
reduction reportedly leads to a significant increase in the
adiponectin level (36). A high level of adiponectin in-
creases insulin sensitivity, while a low adiponectin level
contributes to insulin resistance in obesity and type 2
diabetes mellitus (37). Several studies showed that probio-
tic supplementation may improve adiponectin secretion or
expression (3840).
The level of adiponectin was significantly increased in
the HFD-LcS group after 15 weeks of supplementation,
whereas the blood glucose level was significantly de-
creased, which is consistent with previous studies (27, 41).
Moreover, the adiponectin and glucose levels were sig-
nificantly different in the HFD-LcS and HFD-orlistat
groups compared with the HFD group. These results are
consistent with previous studies (34, 38) that demonstrated
Fig. 2. Histological analysis. a) Adipose tissue, b) liver tissue. SD: standard diet; HFD: high-fat diet; HFD-LcS: high-fat diet
supplemented with LcS; HFD-orlistat: high-fat diet treated with orlistat. Size of adipocytes in SD group59.8 mm, HFD
group374.8 mm, HFD-LcS group156.5 mm, HFD-orlistat group192.2 mm. Black arrows in liver tissue show the fat
visuals.
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the efficacy of probiotic supplementation in terms of
adiponectin and glucose secretion.
Previous studies suggest there is low-grade inflamma-
tion in obesity along with altered levels of several
circulating factors, such as increases in the plasma levels
of TNF-a, CRP, IL-6, and other biological markers of
inflammation (42, 43). Obesity is also associated with a
chronic inflammatory response, which is characterized by
the activation of some pro-inflammatory signaling path-
ways and the abnormal production of adipokines such as
leptin (44). In the present obesity model, there were no
significant differences in the concentrations of inflamma-
tory biomarkers, except for that of IL-6, which may be due
to the level of obesity reached after 12 weeks. The effects of
probiotics on inflammatory biomarkers are controversial.
Cytokine production is assumed to be modulated by
probiotics; however, this effect is strain-specific (45),
possibly due to the surface antigens of bacteria (46). The
comparison of inflammatory biomarkers among the
groups revealed a significant reduction in the level of IL-
6 in the HFD-LcS and HFD-orlistat groups, with no
significant changes in the levels of TNF-a or CRP, which
was consistent with the results of previous studies (46, 47).
At week 27, the HDL level was significantly higher in
the HFD-LcS group than in the HFD group, with no
significant changes in the other lipid profile biomarkers,
which may be due to the bacterial strain. There are
controversial results regarding the effect of probiotics on
the lipid profile. Kang et al. (8) reported there are no
significant changes in the lipid profile of rats supplemen-
ted with Lactobacillus gasseri BNR17. By contrast, several
studies established the hypocholesterolemic effects of some
bacterial strains, including Lactobacillus acidophilus (48)
and Bifidobacterium longum (49).
Similar to previous studies (1, 31), the ALT level was
significantly lower in the HFD-LcS group than in the
HFD group. The current study also revealed that probiotic
supplementation of obese rats did not affect the morphol-
ogy of the liver in comparison to the control group.
Serological and histological results indicated that LcS
supplementation did not damage the liver.
Anti-obesity effects of LcS vs. orlistat
Orlistat is a hydrogenated derivative of a bacterial lipase
inhibitor that plays a role in body weight reduction in
overweight and obese individuals (50). Previous studies
indicated that receiving orlistat three times per day results
in a 30% reduction in body weight in obese individuals
(51). The mechanism of actions of LcS and orlistat are
similar, and both reduce body weight by decreasing the
leptin level and adipocyte size. In the present study,
probiotic supplementation and orlistat treatment had
similar anti-obesity effects. However, LcS administration
showed better results in reducing fat mass and ALT level in
liver.
In conclusion, we suggest that LcS, as used in this
study, has beneficial anti-obesity effects but does not have
anti-inflammatory or hypolipidemic effects. To the best of
our knowledge, no study has compared and analyzed the
anti-obesity effects of the probiotic strain LcS with those
of a drug. Therefore, long-term clinical trials in humans
are needed to investigate the anti-obesity effects of LcS
and its related underlying mechanisms in order to explore
its efficacy as an alternative treatment for obesity.
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